Dinsdag 17 januari 2023 door: Ethan Huff
Tags : landbouw, dieren, slechte gezondheid, badmedicine, badscience, Bayer, Big Pharma, BioNTech, Gecensureerde wetenschap, samenzwering, Gevaarlijke
geneeskunde, misleiding, voedselvoorziening, vee, Merck, mRNA, Pfizer, farmaceutische
fraude, onderzoek, Robert Malone, wetenschappelijk
bedrog, vaccinoorlogen, vaccins, dieren in het wild, Zoetis
Dit artikel kan verklaringen bevatten die de mening van de auteur
weerspiegelen
11KWEERGAVEN
(Natural
News) BioNTech heeft de afgelopen zes jaar met de hulp van Bayer gewerkt aan
"nieuwe, eersteklas" messenger-RNA (mRNA) -vaccins en andere
therapeutica voor dieren. En volgens Dr. Robert Malone (*), ze zijn bijna klaar voor openbare
publicatie.
Meer dan vier jaar voor het verschijnen van covid
waren deze twee farmaceutische bedrijven begonnen met het ontwikkelen van
mRNA-therapeutica voor vee en zelfs gezelschapsdieren - hoewel er geen openbaar
beschikbare klinische proefgegevens zijn voor deze nieuwe geneesmiddelen.
Om welke reden dan ook, de enige beschikbare
informatie omvat persberichten, conferentienota's, subsidie- en
contractmeldingen van het Amerikaanse ministerie van landbouw (USDA), "af
en toe peer-reviewed paper", zoals Dr. Malone schrijft en andere weetjes.
(Gerelateerd: een Australische studie heeft al gevonden dat mRNA-injecties dodelijk zijn voor vee,
waardoor 18 procent van hen onmiddellijk is gestorven in tests.)
Niets van dit alles is volgens hem toereikend en
ook niet transparant. Volgens de wet heeft Big Pharma de verplichting om
gegevens over klinische proeven vrij te geven, vooral wanneer Amerikaanse
belastingdollars worden gebruikt om het onderzoek erachter te financieren.
Dr. Malone was in staat om de beschikbare
informatie samen te voegen om een duidelijker overzicht te geven van wat er op
dit moment werkelijk aan de hand is. In wezen kan iedereen die commercieel
geproduceerd vlees consumeert, binnenkort worden blootgesteld aan
mRNA-vergiften op hun bord.
De mRNA-productiefaciliteiten
van Bayer werden ook gebruikt om covid-vaccins te vervaardigen
Er zijn drie mRNA-therapieplatforms waaraan BioNTech-Bayer heeft gewerkt voor dieren: vaccins tegen
infectieziekten, immunotherapieën voor kanker en eiwitvervanging (protein replacement).
We weten ook dat Bayer, hoewel dit onderzoek de afgelopen zes
jaar heeft plaatsgevonden, zijn mRNA-vaccinproductiefaciliteiten heeft
uitgeleend voor gebruik in de productie van covid-vaccins voor mensen.
Aangezien de globalisten het grote publiek als menselijk vee
beschouwen, is het alleen maar passend dat mRNA-technologieën die voor dieren
zijn ontworpen, ook zijn ontwikkeld voor de menselijke 'kudde' onder Operatie Warp Speed.
Merck & Co., die een minimale rol
speelde in de covid scamdemic, heeft stilletjes mRNA-vaccins voor varkens
geproduceerd en verkocht, vond Dr. Malone ook.
"Om welke reden dan ook, ze verkopen deze producten als
'aangepaste voorgeschreven vaccins tegen stammen van het influenza A-virus bij
varkens, varkenscircovirus (PCV), rotavirus en verder'," schrijft hij.
“Dit is een interessant marktsegment."
"De reden van Merck om de productie van mRNA-vaccins in de
markt voor 'aangepaste recept' te beperken, is onduidelijk. De grootte en
schaalbaarheid van de productiefaciliteit [sic] van het RNA-product kunnen
factoren zijn."
Rond 2014 of 2015 heeft de USDA een voorwaardelijke licentie
afgegeven aan Merck Animal Health om deze mRNA-injecties bij varkens te gaan
gebruiken. Die voorwaardelijke licentie is vergelijkbaar met de Emergency
Use Authorization (EUC) -status die de Amerikaanse Food and Drug
Administration (FDA) heeft afgegeven om de covid vaccins aan mensen te geven op
het hoogtepunt van de plandemie.
"Net als bij het mRNA COVID-19-vaccin werd geen volledige
licentie verleend, maar blijft de voorwaardelijke licentie van kracht",
schrijft Malone. “Is dit een strategie om het USDA-vaccinlicentie- en / of
autorisatieproces te omzeilen?"
Dan hebben we Pfizer,
waarvan de afdeling diergezondheid bekend staat als Zoetis. Zoetis houdt zijn activiteiten voor de ontwikkeling van
dierenvaccins dicht bij zich, dus er is weinig bekend over wat dit bedrijf de
laatste tijd heeft gedaan.
Er zijn ook vor dieren in het wild mRNA prikken momenteel in de maak. Het lijkt erop dat het plan is om alles
wat leeft te injecteren met mRNA, waarvan we weten dat het
de natuurlijke genetische code verandert.
"Blijkbaar hebben ze nog niet genoeg van de mensheid gedood
of gewond", schreef een commentator over al deze drugsabominaties die
worden losgelaten. Nu richten ze zich op de dieren."
More related news coverage can be found at Vaccines.news.
Bronnen voor dit artikel zijn onder meer:
(*)
mRNA Vaccines in
Livestock and Companion Animals are here now.
The
current (public) receipts are included in this essay, and more are on the way
Before we can discus mRNA vaccines for livestock, pets and
wildlife, we must first address the elephant in the room. That is, how come the
public is able to access human clinical trial information, but is not able to
do the same for clinical trials involving animal health?
During the early
days of the AIDS epidemic, the AIDS community demanded public access to
clinical trials. In 1988, the U.S. Congress passed the Health Omnibus
Programs Extension Act of 1988 (Public Law 100-607) which mandated the
development of a database of AIDS Clinical Trials Information Services. This
Congressional Act motivated other non-profit disease related groups to demand
access also.
The Food and
Drug Administration Modernization Act of 1997 amended the Food, Drug and
Cosmetic Act and the Public Health Service Act to require that the NIH create a
publicly available clinical trials database. This eventually led to the
development of the website ClinicalTrials.gov. This allowed tracking of
drug efficacy studies resulting from approved Investigational New Drugs
(including vaccines).
The law requires
(from Wiki):
·
Federally and privately funded clinical
trials;
·
The purpose of each experimental drug;
·
Subject eligibility criteria to
participate in the clinical trial;
·
The location of clinical trial sites
being used for a study; and
·
A point of contact for patients
interested in enrolling in the trial.
·
The National Library of Medicine in the
National Institutes of Health to host the public website/database
(BTW, one of my
former clients held the federal contract to support ClinicalTrials.gov and
Pubmed. I have spent time in the back rooms of the NLM and do know a fair
amount about these things….)
The searchable
ClinicalTrials.gov website was made available to the public via the internet on
February 29, 2000.
ClinicalTrials.gov
makes searching for human clinical trials easy. For instance, a quick
search reveals that there are over 50 clinical trials for mRNA vaccines in
progress and over 200 registered.
With animals,
there is no such database. mRNA vaccines in the “animal health” or
veterinary markets are difficult to track until the company or the USDA is
ready to release information on that product’s development or release. The USDA
and/or the NIH have no mechanism for tracking potential new vaccines, drugs or
biologics for the animal market.
Therefore, one
must rely on press releases, the occasional peer reviewed paper, conference
notes, USDA grant and contract notifications, university websites and company
profiles for discovery of such new products. Not adequate, in my opinion, and
most definitely not transparent. By federal law, the public should have open
access to the results of this type of federally funded research.
In today’s
substack, the state of mRNA “vaccines” for animal “health” is discussed.
Citing public sources, I will review what is known and not known about
commercial liaisons and partnerships, the corporations involved, ongoing
research and products in various states of development.
Bayer Partners with BioNTech to
Develop mRNA Vaccines, Drugs for Animal Health
Genetic
Engineering and Biotechnology News. May 10, 2016
Bayer will
partner with BioNTech to develop novel, first-in-class mRNA vaccines and
therapeutics for animal health indications, the companies
said today, under a collaboration whose value was not disclosed.
Bayer agreed to
secure exclusive rights to BioNTech’s mRNA technology and intellectual property
for development of mRNA vaccines for animal health applications…
The companies
said their partnership is the first of its kind focused on developing mRNA
therapeutics specifically for animal health applications.
…
Infectious
disease vaccines is the focus of one of the three therapy platforms BioNTech is
building through mRNA technologies; the other two are cancer immunotherapies
and protein replacement. The three platforms are designed to produce
pharmacologically optimized protein coding RNA for targeted in vivo delivery…
2016. This means
that Bayer and BioNTech have been working on livestock and companion animal
mRNA vaccines for over six years…
Logic predicts
that they will soon have livestock and companion mRNA vaccine and RNA
therapeutics on the market.
Bayer, BioNTech developing new mRNA
vaccines
Feedstuffs.com
May 16, 2016
Companies collaborate
on cutting-edge technology to develop new solutions to protect companion and
farm animal health.
Again, note the
date…2016. This means that Bayer and BioNTech have been working on livestock
and companion animal mRNA vaccines for over six years…
There are three
therapy platforms that BioNTech has been building through mRNA technologies to
be used in livestock and companion animals.
·
Infectious disease vaccines
·
Cancer immunotherapies and
·
Protein replacement.
Bayer to manufacture mRNA vaccine in
Germany
Bayer
Website, February 1, 2021
"Following
discussions with the German government it has become clear that current
manufacturing capacities for vaccines need to be increased, particularly for
potential variants of the SARS-CoV-2 virus.
This includes the need to
expand production capacity as well as related manufacturing expertise in
Germany.
We at Bayer will contribute
even further by making more vaccine available to help fight the pandemic.
So, Bayer lent
their mRNA manufacturing vaccine facilities for use for the making of COVID-19
mRNA vaccines. Given the above 2016 press releases, that Bayer and BioNtech
were collaborating to make mRNA vaccines for the animal markets, it would make
sense that these facilities were actually built for the production of
veterinary vaccines.
SEQUIVITY: Custom Swine Vaccines,
using RNA vaccines.
Merck
Website, Accessed Jan 2023
Combat current
and future swine diseases with SEQUIVITY from Merck Animal Health. A revolutionary swine vaccine platform, SEQUIVITY
harnesses RNA particle technology to create customized
prescription vaccines against strains of influenza A virus in swine, porcine
circovirus (PCV), rotavirus and beyond. It’s supported by a sophisticated
dashboard filled with comprehensive data and insights, all to help you stay on
top.
Important to
know. Merck is already selling mRNA vaccines for swine. For whatever reason,
they are selling these products as “customized prescription vaccines against strains of
influenza A virus in swine, porcine circovirus (PCV), rotavirus and beyond.”
This is an interesting market segment. Merck’s reason to limit the production
of mRNA vaccines in the “customized prescription” market
is unclear. Production facility size and
scaleability of the RNA product could be factors.
Acquisition Expands and Complements
Merck Animal Health’s Strong Vaccine Portfolio
Merck
Press Release, November 12, 2015 5:00 pm ET
MADISON, N.J., November 12,
2015 – Merck Animal Health (known as MSD Animal Health outside the United
States and Canada) and Harrisvaccines, Inc., today announced the companies have
entered into an agreement under which Merck Animal Health will acquire Harrisvaccines,
a privately-held company that develops, manufactures and sells vaccines for
food production and companion animals.
“As a leader in
biologics, Merck Animal Health has built a robust portfolio of vaccines across
all animal species,” stated Rick DeLuca, president, Merck Animal Health.
“Combining Harrisvaccines’ R&D and portfolio of products with our strong
capabilities and global reach will enable us to address even more devastating
diseases that are impacting production animals and reinforce our commitment to
the science of healthier animals.”
Harrisvaccines
offers innovative technology and an important portfolio of
vaccines, with a focus on production animals, an increasingly important
segment as consumer demand for protein continues to grow worldwide. The company has a unique RNA
Particle technology which represents a breakthrough in vaccine development. It
also has a highly versatile production platform able to target a wide range of
viruses and bacteria. Pathogens are collected from a farm and specific genes
are sequenced and inserted into RNA particles, making safe, potent vaccines
able to provide herd-specific protection.
This pioneering
system is rapidly adaptable to new disease challenges and was instrumental in
producing the first conditionally licensed vaccine to help control Porcine
Epidemic Diarrhea Virus (PEDv), a deadly virus that has killed more than eight
million piglets since suddenly emerging in the U.S. in 2013.
Read that last
paragraph again. Slowly.
Sometime before
2015, the USDA issued a conditional license for a mRNA vaccine for use in pigs
for Porcine Epidemic Diarrhea Virus
(PEDv), information about this product can be found at drugs.com.
Basically
something akin to an emergency use authorization was issued around 2014 or
2015. Just like with the mRNA COVID-19 vaccine, full licensure was not granted
but the conditional license remains in place. Is this a strategy to circumvent
the USDA vaccine licensing and/or authorization process?
To conclude:
Like with the
BioNtech’s veterinary mRNA vaccine development, Merck’s development of an mRNA
vaccine product started years ago. For Merck, it may have begun in earnest in
2015 with the acquisition of Harris Vaccine.
Some ongoing
research:
NOVEL MRNA VACCINE TECHNOLOGY FOR PREVENTION
OF BOVINE RESPIRATORY SYNCYTIAL VIRUS
IOWA
STATE UNIVERSITY (grant summary page)
Non Technical
Summary
Bovine
respiratory syncytial virus (RSV) is a significant viral pathogens of young
cows that is a key component of the respiratory disease complex and often leads
to secondary bacterial pneumonia. Prefusion F has recently shown to be highly
efficacious in barrier housed RSV challenged cows. However, the difficulty in
generating prefusion F along with the cost of its production are a hurdle for adoption
to the farm. RSV immunity also tends to wane quickly and given the
complications of field or pen raised cattle and their stressors and other
circulating diseases, and a protein vaccine may not prove highly efficacious in
the real world. Here, we will test a novel mRNA vaccine system we have
developed that substantially lowers the price point for production animals and
may lead to more thermal stable transcripts compatible with vaccinating on the
farm. The use of an alternative delivery system rather than lipid nanoparticles
will also lower the vaccine costs. We expect to demonstrate efficacy of the
vaccine platform using mice at first as proof of principle before switching to
a full cow vaccination and challenge system in year 2. Our overall goal is to
test a novel mRNA system for inducing immunological protection from bovine RSV
infection. We hypothesize that a prefusion F mRNA delivered continuously by
vaccine implant will lead to prolonged and robust cellular and antibody
immunity. Here, we will optimize our vaccine further and then test for
potential correlates of protection to examine for in eventually challenged
cows.
Research into
mRNA vaccine livestock vaccines in New Zealand and Australia continues with
governmental fast-track approval.
NSW fast tracks mRNA FMD and Lumpy
Skin Disease vaccines (in cattle)
The
NSW Government has taken another step towards fast tracking the world first
mRNA vaccines for Foot and Mouth Disease (FMD) and Lumpy Skin Disease, inking a
deal with US biotechnology company Tiba Biotech
A Foot and Mouth Disease mRNA
Vaccine Deal Has Been Signed Between the NSW Government and US Company Tiba
Biotech
Finally,
inquiring minds want to know… what is Pfizer up to?
Pfizer animal
health goes by the name Zoetis.
Zoetis clearly
does not make its animal vaccine developmental stages known to the public.
Internet searches do not reveal much inside the workings of Zoetis, in terms of
mRNA vaccines. However, we can safely assume that development of mRNA vaccines
and therapeutics for “animal health” are underway - so stay tuned.
Finally, there
are mRNA vaccines for COVID-19 for wildlife that have been developed and
authorized for distribution by the USDA.
Black-footed ferret COVID-19
vaccination seems to be working
The
Wildlife Society, Feb 18, 2021
After finding
similar species can be infected, researchers quickly began to increase safety protocols at zoos
and the U.S. Fish and Wildlife Service’s National Black-footed Ferret
Conservation Center in Colorado, the main source of the captive-breeding and
release program for the federally endangered species.
“They have done
a magnificent job in keeping those animals safe,” said Tonie Rocke, a research
scientist with the USGS National Wildlife Health Center who works with ferrets.
But U.S.
Geological Survey researchers who also study black-footed ferrets had learned
about recent studies in mice and hamsters, demonstrating safety and efficacy of
vaccination against COVID-19 using purified viral protein. They decided to try
something similar on a handful of ferrets this past May and June.
The vaccine used
in ferrets is different — it’s a simplified version of the Moderna or Pfizer
vaccinations now being used for humans — and it’s
based on a similar protein, said Rocke.
Under the
authority of the USFWS, the scientists could test the solution on a handful of ferrets
in a process that is much quicker than the extensive approvals needed for
commercial vaccination for humans like the Pfizer or Moderna inoculations.
The isolated
ferrets that had received this trial vaccination produced antibodies against
the coronavirus.
Unfortunately, I
could find no updates to this program and whether it was expanded into other
wildlife populations.
Again, something
akin to an emergency use authorization was issued for this experimental
vaccine. Just like with the mRNA COVID-19 vaccine and the RNA porcine vaccine
above, full licensure was not granted but it appears that the conditional
license remains in place. I raise the question again, is this a USDA and/or
corporate strategy to circumvent the USDA vaccine licensing and/or authorization
process?
The issue being
of course, that there is no mechanism for “right to know” of animal health
vaccine development.
There were news
stories in 2020 that mRNA vaccine(s) were being developed for COVID/SARS-CoV-2
for administration to livestock and companion animals. However, the lack of
updates suggest that these plans may have been scrapped with the new, less
virulent variants.
Who is Robert
Malone is a reader-supported publication. To receive new posts and support my
work, consider becoming a free or paid subscriber.
Source: https://rwmalonemd.substack.com/p/mrna-vaccines-in-livestock-and-companion
